The impact of remote learning on your child’s vision
Roshni Patel BSc (Hons) MCOptom, Professional Services Manager at Lenstore, discusses how learning at home and spending more time indoors might have an effect on your child’s eyes and what you can do to mitigate any problems.
97.2% of in-person COVID test results returned the next day
NHS Test and Trace turnaround times continue to rise as 97.2% of in-person COVID test results are returned the next day.
Over 10 million people receive COVID-19 vaccine
UK reaches significant milestone as more than 10 million people receive the first dose of the COVID-19 vaccine.
Clinical trial looks into mixing different COVID-19 vaccines
A world-first clinical trial looking into mixing different COVID-19 vaccine doses has been backed by £7 million of government funding.
Patient flow and bed management: How does your Trust manage it?
Paul Barrett, TeleTracking UK, explains how automating patient flow and bed management in real-time can transform hospital operations, free up time for nurses to care, reduce stress on caregivers and importantly improve patient outcomes.
Orthodox Jew’s have one of the highest COVID-19 infection rates
A new study has found that the UK strictly-Orthodox Jewish community experience one of the highest infection rates of COVID-19 throughout 2020.
Research says 12 weeks between AstraZeneca doses improves protection
AstraZeneca dose efficiency holds at 76% in the three-month period between the first and second dose - suggesting that this time period is good for maximising protection.
Data shows young, Black adults twice as likely to die after heart transplant
The American Heart Association found that young, Black adults are more than twice as likely to die in the first year after a heart transplant - in comparison to non-Black transplant recipients of the same age.
High infection numbers can undo our vaccination programmes
The vaccine roll out gives hope of a return to some form of normality, but current high COVID-19 infection numbers put the success of vaccination programmes at risk. Professor Martin Michaelis and Dr Mark Wass of University of Kent’s School of Biosciences explain why.
South African COVID-19 variant found in UK
Additional testing has been deployed across the UK after a COVID-19 variant originally identified in South Africa has been found .
UK purchases additional 40 million doses of Valneva vaccine
The UK government has announced that it has secured early access to a further 40 million doses of the Valneva COVID-19 vaccine.
Third of Americans say they are unlikely to get COVID-19 vaccine
A new study by the University of California, Davis has found that a third of Americans are either unlikely or hesitant to get a COVID-19 vaccine when it becomes available.
Johnson & Johnson vaccine has 66% efficiency in one dose
New clinical trial data shows that the Johnson & Johnson vaccine is able to give 66% protection against COVID in one dose - with an 85% efficiency at the standard double-dose.
The EU authorises AstraZeneca COVID vaccine for use
European regulators have approved their third vaccine, AstraZeneca - which comes after a week of tense communications between the two parties.
Three ways to solve the logistical challenges of giving COVID vaccines
An anonymous Doctor explains their ideas for how the NHS could tackle the significant logistical challenges of giving COVID vaccines.
Novavax vaccine is 85.6% efficient against UK COVID mutation
Phase Three data from the UK trial shows that Novavax still works powerfully against the UK mutation, with a less intense impact on the South African mutation at 60%.
Engineers design model for using one ventilator on two patients
Engineers at the University of Bath have published a mathematical model that could help clinicians to safely ventilate two COVID patients on one ventilator.
Is this a vaccine war or the first post-Brexit war?
Right now, the rift between AstraZeneca and the European Commission continues to grow - but is it a vaccine war or the first post-Brexit war?
REACT study: UK scientists aren’t seeing a “sharp drop in infections”
New data from the REACT study finds that the rising infection rate has steadied a little, but there is no "sharp drop in infections" as in the first wave and the R is still high.
AstraZeneca CEO discusses the European Commission vaccine feud
AstraZeneca CEO Pascal Soriot spoke to Antonello Guerrera about the ongoing vaccine feud - with the Commission receiving 60% less than expected, raising tense questions about why.